Prior to joining Synthetic Biologics, Dr. Gottlieb was the senior medical director of therapeutic strategy – gastroenterology at Fortune 500 company Quintiles, according to the report.
Dr. Gottlieb will provide further leadership support as Synthetic Biologics moves forward with Phase 2 clinical trials for its irritable bowel syndrome and Clostridium difficile products.
He will report directly to Joseph Sliman, MD, MPH, senior vice president of clinical and regulatory affairs.
More articles on gastroenterology:
Lovell Federal Health Care Center opens new GI center
5 most-read GI/endoscopy stories – May 25 to May 29
13 GI physicians making headlines – May 26, 2015
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.